Last reviewed · How we verify
NCT03160768
Feasibility of Isolating P16 Expression
trial in Childhood Cancer in 85 participants. Completed in 2 May 2019.
2 May 2019
Quick facts
| Lead sponsor | St. Jude Children's Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 85 |
| Start date | 25 May 2017 |
| Primary completion | 2 May 2019 |
| Estimated completion | 2 May 2019 |
| Sites | 1 location across United States |
Conditions studied
- Childhood Cancer — all drugs for Childhood Cancer →
Sponsor
St. Jude Children's Research Hospital
Who can join
18 and older, any sex, with Childhood Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Expression of the cell cycle regulator p16INK4a increases with age and toxic stressors. In mice, both radiation and chemotherapy are known to increase p16. Due to its influence on age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic reserve that may identify patients able to withstand the stressor of chemotherapy (low p16) from those unlikely to tolerate chemotherapy (high p16). That is, expression of p16 may predict physiologic, rather than chronologic, age. Such findings could have implications for care of cancer survivors and treatment decision-making in cancer patients. STUDY OBJECTIVE: This is an observational pilot study to determine the feasibility of isolating p16INK4a in CD3+ T lymphocytes in adults treated with chemotherapy for cancer during childhood.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03160768
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Childhood Cancer
Currently open trials in the same condition.
- NCT06839794 — Effect of Cognitively Challenging Physical Activity on Executive Functions in Pediatric Cancer Patients · NA · recruiting
- NCT06609473 — Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Surviv · NA · recruiting
- NCT06854822 — Siblings to a Child with Cancer: Needs and Pre-loss Grief · recruiting
- NCT06769334 — Preparing for Life and Academics for Young Childhood Cancer Survivors · NA · recruiting
- NCT06053268 — Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors · NA · active not recruiting
Other St. Jude Children's Research Hospital trials
Trials by the same sponsor.
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
- NCT07085338 — A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat · Phase 2 · recruiting
- NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
- NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
- NCT06326463 — CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03160768 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Jude Children's Research Hospital
- Last refreshed: 6 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03160768.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing